AURINIA PHARMACEUTICALS INC's ticker is AUPH and the CUSIP is 05156V102. A total of 200 filers reported holding AURINIA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,597,474 | -45.3% | 1,106,496 | -31.9% | 0.00% | -66.7% |
| Q2 2023 | $15,720,184 | -27.3% | 1,623,986 | -17.7% | 0.00% | -25.0% |
| Q1 2023 | $21,628,870 | +203.6% | 1,973,437 | +19.6% | 0.00% | +100.0% |
| Q4 2022 | $7,125,244 | -55.5% | 1,649,362 | -22.5% | 0.00% | -50.0% |
| Q3 2022 | $16,006,000 | -52.8% | 2,128,581 | -36.9% | 0.00% | -50.0% |
| Q2 2022 | $33,895,000 | -40.1% | 3,372,567 | -26.2% | 0.01% | -20.0% |
| Q1 2022 | $56,594,000 | -81.7% | 4,571,405 | -66.2% | 0.01% | +11.1% |
| Q4 2021 | $309,344,000 | +117.3% | 13,526,212 | +110.2% | 0.01% | -50.0% |
| Q3 2021 | $142,378,000 | +129.0% | 6,433,727 | +34.1% | 0.02% | +100.0% |
| Q2 2021 | $62,187,000 | +69.6% | 4,798,382 | +69.9% | 0.01% | +50.0% |
| Q1 2021 | $36,666,000 | -60.3% | 2,823,734 | -57.7% | 0.01% | -14.3% |
| Q4 2020 | $92,356,000 | +155.4% | 6,677,994 | +172.1% | 0.01% | 0.0% |
| Q3 2020 | $36,155,000 | +21.0% | 2,454,478 | +33.5% | 0.01% | 0.0% |
| Q2 2020 | $29,870,000 | +10.0% | 1,838,199 | -1.8% | 0.01% | -22.2% |
| Q1 2020 | $27,149,000 | -27.2% | 1,871,051 | +1.6% | 0.01% | -18.2% |
| Q4 2019 | $37,303,000 | +284.4% | 1,841,270 | +1.3% | 0.01% | +266.7% |
| Q3 2019 | $9,705,000 | -59.2% | 1,817,436 | -49.8% | 0.00% | 0.0% |
| Q2 2019 | $23,814,000 | +254.5% | 3,619,451 | +250.2% | 0.00% | 0.0% |
| Q1 2019 | $6,718,000 | +99.3% | 1,033,462 | +109.2% | 0.00% | +200.0% |
| Q4 2018 | $3,370,000 | -2.6% | 494,034 | -5.2% | 0.00% | – |
| Q3 2018 | $3,459,000 | +26.4% | 520,979 | +7.1% | 0.00% | – |
| Q2 2018 | $2,737,000 | +38.0% | 486,221 | +27.2% | 0.00% | – |
| Q1 2018 | $1,984,000 | +22.5% | 382,328 | +7.0% | 0.00% | – |
| Q4 2017 | $1,619,000 | -60.4% | 357,460 | -45.1% | 0.00% | -100.0% |
| Q3 2017 | $4,085,000 | -7.8% | 651,476 | -9.8% | 0.00% | -66.7% |
| Q2 2017 | $4,429,000 | -17.2% | 722,533 | -0.9% | 0.00% | 0.0% |
| Q1 2017 | $5,351,000 | +85.3% | 729,028 | -47.0% | 0.00% | +200.0% |
| Q4 2016 | $2,888,000 | – | 1,375,053 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blackcrane Capital, LLC | 503,248 | $6,535,000 | 10.30% |
| Prosight Management, LP | 360,834 | $4,685,000 | 3.84% |
| Healthcare Value Capital, LLC | 100,000 | $1,299,000 | 2.89% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,748,208 | $22,700,000 | 2.32% |
| DG Capital Management, LLC | 591,154 | $7,676,000 | 1.83% |
| NEA Management Company, LLC | 5,172,683 | $67,193,000 | 1.51% |
| Altium Capital Management LP | 408,908 | $5,310,000 | 1.47% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 170,316 | $2,212,000 | 1.17% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 298,500 | $3,875,000 | 1.02% |
| KNOTT DAVID M | 154,840 | $2,011,000 | 0.86% |